News Articles

Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate... CAMBRIDGE, Mass. & OSAKA, Japan -Wednesday 27 November 2019    

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib in adults with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who had not...

Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical... -Tuesday 26 November 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502 / NYSE:TAK) (“Takeda”) today announced that updated results from the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue vaccine candidate (TAK-003) were presented at...

Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology... -Friday 15 November 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that it will present a total of 29 company-sponsored abstracts at the 61st American Society of Hematology (ASH) Annual Meeting on December 7-10, 2019 in Orlando, FL, highlighting the company’s...

Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D... -Thursday 14 November 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host an R&D meeting today beginning at 12:30 p.m. EST in New York City to outline how its science-first, patient-centric strategy, diverse portfolio of approved medicines and its R&D engine is...

Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple... -Sunday 10 November 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda") today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first...

New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and... -Friday 8 November 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO® (lanadelumab-flyo) injection in patients with hereditary angioedema (HAE) 12 years of age and older...

Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of... -Thursday 7 November 2019  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that results from the primary endpoint analysis of the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue vaccine candidate...

Takeda Unveils New Dengue Vaccine Manufacturing Plant in Germany -Thursday 7 November 2019  

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the opening of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003. The Singen vaccine plant will be utilized for formulation, fill, finish and...

Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell... -Wednesday 6 November 2019  

(BUSINESS WIRE)-- The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer...

Takeda Continues Strategic Divestitures With Sale of Select OTC and Non-Core Assets to STADA for $660 Million USD -Tuesday 5 November 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select products to STADA Arzneimittel AG (“STADA”), an international pharmaceutical company, for a total value of $660...

Takeda Reports Solid Second Quarter FY2019 Results and Raises Profit Guidance for the Full Year -Sunday 3 November 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): Underlying Revenue declined -0.2% vs FY2018 H1 pro-forma revenue2 Takeda’s 14 global brands with reported revenue of 547.0 billion yen in aggregate posted a strong year-over-year underlying growth of...

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a... -Wednesday 23 October 2019  

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”) today announced that Takeda has acquired an exclusive global license to develop and commercialize the investigational medicine...

Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFα Therapies in... -Monday 21 October 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from a retrospective chart review study (EVOLVE), which investigated the likelihood of serious adverse events and serious infections with vedolizumab and anti-tumor necrosis...

Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD -Tuesday 15 October 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa (NEMEA)...

New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2... -Friday 27 September 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced results of a Phase 1 clinical proof of concept study of the novel investigational compound TAK-925, a selective orexin type-2 receptor (OX2R) agonist, in individuals with narcolepsy type 1 (NT1)....

First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of... -Friday 27 September 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the VARSITY study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio®) to the anti-tumor necrosis factor-alpha (anti-TNFα)...

New England Journal of Medicine Publishes Results of a Phase 2 Trial Evaluating Takeda’s TAK-620 (Maribavir)... -Tuesday 24 September 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the New England Journal of Medicine has published results of a Phase 2, randomised, 12-week, open-label study of TAK-620 (maribavir), an investigational, orally bioavailable...

Takeda Recognized in the 2019 Dow Jones Sustainability World Index -Thursday 19 September 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has been named in the 2019 Dow Jones Sustainability World Index, achieving more than double the average overall industry score. In addition, Takeda was named for the 10th...

Takeda Announces FY2019 Key Performance Indicators Aligned with Shareholder Value Creation and Focused on Successful... -Friday 2 August 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO: 4502/NYSE: TAK) today announces that the Takeda Board of Directors has approved key performance indicators (KPIs) to be included in both the company’s short-term and long-term incentive plans for fiscal year 2019,...

Takeda Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year -Friday 2 August 2019

Revenue 849.1 billion yen, up +88.8% versus prior year mainly due to acquisition of Shire, with solid performance of 14 global growth brands Strong start with Core Operating Profit* of 283.0 billion, up +142.3% versus FY2018 Q1 and Underlying Core Operating Profit Margin of 32.4% Shire...